Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI North America CPhI North America
Not Confirmed
Not Confirmed
20-22 May, 2025
AACR Annual meetingAACR Annual meeting
Not Confirmed
Not Confirmed
25-30 April, 2025
AOCS Annual MeetingAOCS Annual Meeting
Not Confirmed
Not Confirmed
27-30 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
AACR Annual meetingAACR Annual meeting
Industry Trade Show
Not Confirmed
25-30 April, 2025
AOCS Annual MeetingAOCS Annual Meeting
Industry Trade Show
Not Confirmed
27-30 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels
04 Apr 2025
// HEALTH CANADA
25 Oct 2024
// BUSINESSWIRE
24 Oct 2024
// BUSINESSWIRE
19 Sep 2024
// REUTERS
https://www.reuters.com/markets/deals/organon-buy-therapy-developer-dermavant-up-12-billion-2024-09-18/
25 Jun 2024
// BUSINESSWIRE
21 May 2024
// BUSINESSWIRE
Details:
Vtama (tapinarof) cream is a novel aryl hydrocarbon receptor agonist, in phase 3 trials as a once-daily, steroid-free topical cream for Atopic Dermatitis.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 01, 2024
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dermavant Reports Positive Data from ADORING Program with VTAMA® Cream
Details : Vtama (tapinarof) cream is a novel aryl hydrocarbon receptor agonist, in phase 3 trials as a once-daily, steroid-free topical cream for Atopic Dermatitis.
Product Name : Vtama
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 01, 2024
Details:
Through the acquisition, Organon will leverage the Dermavant pipeline, which includes Vtama (tapinarof) cream. It is indicated for the treatment of f plaque psoriasis in adults.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Organon
Deal Size: $1,200.0 million Upfront Cash: $175.0 million
Deal Type: Acquisition October 28, 2024
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Organon
Deal Size : $1,200.0 million
Deal Type : Acquisition
Organon Acquires Dermavant's VTAMA® Cream for Dermatology
Details : Through the acquisition, Organon will leverage the Dermavant pipeline, which includes Vtama (tapinarof) cream. It is indicated for the treatment of f plaque psoriasis in adults.
Product Name : Vtama
Product Type : Other Small Molecule
Upfront Cash : $175.0 million
October 28, 2024
Details:
Through the acquisition, Organon will leverage the Dermavant pipeline, which includes Vtama (tapinarof) cream. It is indicated for the treatment of f plaque psoriasis in adults.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Organon
Deal Size: $1,200.0 million Upfront Cash: $175.0 million
Deal Type: Acquisition September 18, 2024
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Organon
Deal Size : $1,200.0 million
Deal Type : Acquisition
Organon Pays up to $1.2B to Acquire Dermavant and its Steroid-Free Skin Cream Vtama
Details : Through the acquisition, Organon will leverage the Dermavant pipeline, which includes Vtama (tapinarof) cream. It is indicated for the treatment of f plaque psoriasis in adults.
Product Name : Vtama
Product Type : Other Small Molecule
Upfront Cash : $175.0 million
September 18, 2024
Details:
Vtama (tapinarof) cream is an aryl hydrocarbon receptor agonist steroid-free, topical cream, for the treatment of psoriasis in adults and atopic dermatitis in adults & children 2 years of age & above.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Japan Tobacco Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 25, 2024
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Japan Tobacco Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Dermavant Announces Approval of Tapinarof in both Psoriasis and Atopic Dermatitis in Japan
Details : Vtama (tapinarof) cream is an aryl hydrocarbon receptor agonist steroid-free, topical cream, for the treatment of psoriasis in adults and atopic dermatitis in adults & children 2 years of age & above.
Product Name : Vtama
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 25, 2024
Details:
Vtama (tapinarof) cream is a novel aryl hydrocarbon receptor agonist for once-daily topical treatment of atopic dermatitis in patients 2 years and older.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 29, 2024
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dermavant Announces FDA Acceptance Of sNDA for VTAMA® Cream
Details : Vtama (tapinarof) cream is a novel aryl hydrocarbon receptor agonist for once-daily topical treatment of atopic dermatitis in patients 2 years and older.
Product Name : Vtama
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 29, 2024
Details:
Vtama (tapinarof) cream is a novel aryl hydrocarbon receptor agonist, developed as a once-daily, steroid-free topical cream for atopic dermatitis in adults and children 2 years and older.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 14, 2024
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dermavant Submits sNDA for VTAMA® Cream, 1% for Atopic Dermatitis
Details : Vtama (tapinarof) cream is a novel aryl hydrocarbon receptor agonist, developed as a once-daily, steroid-free topical cream for atopic dermatitis in adults and children 2 years and older.
Product Name : Vtama
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 14, 2024
Details:
Vtama (tapinarof Cream 1%) is the first-in-class, steroid-free, once-daily topical treatment for extensive atopic dermatitis in adults and children as young as two years old.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 01, 2023
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dermavant to Present Data from Multiple Studies of Vtama® (tapinarof) cream, 1% at the 2023 Winte...
Details : Vtama (tapinarof Cream 1%) is the first-in-class, steroid-free, once-daily topical treatment for extensive atopic dermatitis in adults and children as young as two years old.
Product Name : Vtama
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 01, 2023
Details:
Vtama (tapinarof) is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant and steroid-free, topical cream, for the treatment of plaque psoriasis in the head and neck region.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: Phase IVProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 12, 2023
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dermavant Announces Positive Results from Phase 4 Open-Label Trial of VTAMA® (tapinarof) Cream, 1...
Details : Vtama (tapinarof) is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant and steroid-free, topical cream, for the treatment of plaque psoriasis in the head and neck region.
Product Name : Vtama
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 12, 2023
Details:
Vtama (tapinarof Cream 1%) is the first-in-class, steroid-free, once-daily topical treatment for moderate to severe atopic dermatitis in adults and children as young as two years old.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 16, 2023
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vtama (tapinarof Cream 1%) is the first-in-class, steroid-free, once-daily topical treatment for moderate to severe atopic dermatitis in adults and children as young as two years old.
Product Name : Vtama
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 16, 2023
Details:
Vtama (tapinarof Cream 1%) is the first-in-class, steroid-free, once-daily topical treatment for extensive atopic dermatitis in adults and children as young as two years old.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 15, 2023
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vtama (tapinarof Cream 1%) is the first-in-class, steroid-free, once-daily topical treatment for extensive atopic dermatitis in adults and children as young as two years old.
Product Name : Vtama
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 15, 2023
Regulatory Info : RX
Registration Country : USA
Dosage Form : CREAM;TOPICAL
Brand Name : VTAMA
Dosage Strength : 1%
Packaging :
Approval Date : 2022-05-23
Application Number : 215272
Regulatory Info : RX
Registration Country : USA
RLD : Yes
TE Code :
Dosage Form : CREAM; TOPICAL
Proprietary Name : VTAMA
Dosage Strength : 1%
Approval Date : 2022-05-23
Application Number : 215272
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
ABOUT THIS PAGE